Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
18.40
-0.08 (-0.43%)
At close: Jun 26, 2026, 4:00 PM EDT
18.00
-0.40 (-2.17%)
After-hours: Jun 26, 2026, 6:26 PM EDT
Cullinan Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Cullinan Therapeutics stock have an average target of 33.2, with a low estimate of 24 and a high estimate of 46. The average target predicts an increase of 80.43% from the current stock price of 18.40.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cullinan Therapeutics stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 11 | 11 | 11 | 11 | 11 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 12 | 12 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $30 | Buy | Reiterates | $30 | +63.04% | Jun 24, 2026 |
| Wedbush | Wedbush | Buy Maintains $37 | Buy | Maintains | $37 | +101.09% | Jun 11, 2026 |
| BTIG | BTIG | Buy Reiterates $38 | Buy | Reiterates | $38 | +106.52% | Jun 11, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jun 11, 2026 |
| Clear Street | Clear Street | Buy Maintains $33 → $46 | Buy | Maintains | $33 → $46 | +150.00% | Jun 10, 2026 |
Financial Forecast
Revenue This Year
9.23M
Revenue Next Year
44.60M
from 9.23M
Increased by 382.93%
EPS This Year
-3.15
from -3.36
EPS Next Year
-2.53
from -3.15
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 47.3M | 144.3M | |
| Avg | 9.2M | 44.6M | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | 1,463.0% | 110.1% |
| Avg | 382.9% | -29.5% |
| Low | -100.0% | -100.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -2.48 | -0.34 | |
| Avg | -3.15 | -2.53 | |
| Low | -3.54 | -3.73 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.